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j ourna l homepage: www.eb iomed ic ine.comEditorialA Path Forward for ReproducibilityGood science, performed using best practices, may reveal to us funda-
mental biological truths. Our common goal as health science researchers
and practitioners is to make accurate insights into how biological path-
ways truly work and apply them toward keeping ourselves healthy.
When badly conducted science obfuscates or distorts these truths, bio-
medical progress may stall. Resources and time may be wasted on chas-
ing after the wrong therapeutic target. Or worse—health practices could
be misinformed, and patients may become sicker instead of healthier.
Yet, despite these obvious incentives to followbest scientiﬁc practices,
many feel the system is broken—that scientists are not sufﬁciently incen-
tivized for rigor and reproducibility, but instead are rewarded for speed,
productivity, and for publishing in prestigious journals with high impact
factors. These pressures may ultimately discourage careful and rigorous
scientiﬁc practice, and it is upsetting to observe the ever-increasing num-
ber of retractions being published by high impact journals. There is a sen-
timent, in fact, that biomedical research is in themidst of an identity crisis
of sorts—with a number of well-publicized reports over the past few
years claiming that a substantial percentage of published scientiﬁc stud-
ies, spanning several scientiﬁc disciplines, are irreproducible. It is daunt-
ing to imagine the extent of the problem.
Publication of these reports has understandably met with public
alarm as well as deep concern among the research community that
something must be done. It is perhaps also not surprising that the chief
medical ofﬁcer of one of the largest pharmaceutical companies in the
world has just announced in the April 27th issue of Science Translational
Medicine a proposal that academic institutions start ensuring reproduc-
ibility of their data—with a money-back guarantee on collaborative
fundingwhenpreclinical data turn out to bewrong. Froma strict business
standpoint, this disincentive for providing “bad product” probablymakes
sense. It seems practically challenging, however, for academic laborato-
ries to fully ensure that their results are reproducible within multiple bi-
ological contexts and environments—or even to subcontract companies
to do this for them. “Financially-insured” biological data are unlikely to
be hitting the translational science market any time soon, yet ﬁnancial
pressure may be worth debating as one creative approach toward incen-
tivizing reproducibility.
Another recent approach from funding bodies such as the NIH, is to
require applicants to clearly outline within their grant proposals the
speciﬁc steps being taken toward reproducibility. Beginning with
these ﬁrst grant cycles of 2016, applicants must include detailed de-
scription of how they plan to authenticate biological and chemical re-
sources, as well as how they plan to account for biological variables
such as the sex and age of model animals. These are all steps in thehttp://dx.doi.org/10.1016/j.ebiom.2016.05.020
2352-3964/© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NCright direction to help researchers be more cognizant of what measures
they should be taking in their own laboratories to ensure the reproduc-
ibility of their work.
Standardization of reporting is another best practice being widely
adapted by researchers and scientiﬁc journals alike. At EBioMedicine,
we acknowledge our role as editors in promoting reproducibility. We
fully embrace efforts by journals and policy makers aimed at ensuring
scientiﬁc rigor such as the NIH Principles and Guidelines for Reporting
Preclinical Research (https://www.nih.gov/research-training/rigor-
reproducibility/principles-guidelines-reporting-preclinical-research).
All papers accepted at EBioMedicine are subjected to a detailed au-
thors' checklist aimed at ensuring reproducibility, transparency, and
accessibility of the paper's data. Just as an example, we ask that all animal
studies follow ARRIVE guidelines, and that clinical trials follow CONSORT
guidelines. These checklists are now standard practice for many journals,
and are designed to facilitate reproducibility by providing as much de-
tailed information as possible about the experimental design and logic,
aswell as anybiological variables thatmay confound the results. Although
we agree that every detail might not always seem immediately relevant
at face value—in addition to obviously pertinent information such as sta-
tistical details,we encourage our authors to provide sufﬁcient information
to replicate each experiment successfully.
Non-proﬁt organizations such as the Global Biological Standards In-
stitute have also been recently established in an attempt to assure re-
producibility. The mission of GBSI is in part to create a movement and
awareness toward standardizing and authenticating biological reagents
such as cell lines and antibodies, and to educate researchers on how to
ensure best practices regarding biological standards.
The publication of negative results is also an important consider-
ation in the context of reproducibility. When landmark studies, in par-
ticular, cannot be replicated, it is essential that this information
becomes part of the scientiﬁc discourse. Although negative results
may not always be considered as impactful and exciting as positive
ones, setting the record straight is essential for moving the ﬁeld away
from dead-end hypotheses and irrelevant therapeutic targets.
Although the issue of irreproducibility in science may be unsettling,
at EBioMedicine, we join the ranks of scientists and publishers who are
taking a proactive, positive view toward changing the landscape to fos-
ter better scientiﬁc practice.
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